Literature DB >> 18723477

Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.

Hongtao Gu1, Xiequn Chen, Guangxun Gao, Hongjuan Dong.   

Abstract

Multiple myeloma is an incurable plasma cell malignancy. The 26S proteasome inhibitor, bortezomib, selectively induces apoptosis in multiple myeloma cells; however, the mechanism by which this compound acts remains unknown. Here, we, using immunoblotting analysis, observed that the expression of BiP, CHOP, and XBP-1 is up-regulated in bortezomib-induced apoptosis in human multiple myeloma cell lines NCI-H929 and RPMI-8226/S, strongly suggesting that endoplasmic reticulum (ER) stress response or the unfolded protein response (UPR), a signaling pathway activated by the accumulation of unfolded proteins within ER, is initiated. In the meantime, we also showed that bortezomib inhibited classic ER stressor brefeldin A-induced up-regulation of prosurvival UPR components BiP and XBP-1, resulting in increased induction of apoptosis in multiple myeloma cell lines, raising the possibility that bortezomib induces apoptosis of multiple myeloma cells by means of evoking the severe ER stress but disrupting the prosurvival UPR required. Using caspase inhibitors and a RNA interference approach, we finally confirmed that bortezomib-triggered apoptosis in multiple myeloma cells is dependent on caspase-2 activation, which is associated with ER stress and required for release of cytochrome c, breakdown of mitochondrial transmembrane potential, and its downstream caspase-9 activation. Taken together, these data strongly suggest that caspase-2 can serve as a proximal caspase that functions upstream of mitochondrial signaling during ER stress-induced apoptosis by bortezomib in multiple myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723477     DOI: 10.1158/1535-7163.MCT-08-0186

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  27 in total

Review 1.  Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

Review 2.  Advances in the understanding of mechanisms and therapeutic use of bortezomib.

Authors:  Taskeen Mujtaba; Q Ping Dou
Journal:  Discov Med       Date:  2011-12       Impact factor: 2.970

3.  TAp73alpha protects small cell lung carcinoma cells from caspase-2 induced mitochondrial mediated apoptotic cell death.

Authors:  Naveen Muppani; Ulrika Nyman; Bertrand Joseph
Journal:  Oncotarget       Date:  2011-12

4.  ER stress, mitochondrial dysfunction and calpain/JNK activation are involved in oligodendrocyte precursor cell death by unconjugated bilirubin.

Authors:  Andreia Barateiro; Ana Rita Vaz; Sandra Leitão Silva; Adelaide Fernandes; Dora Brites
Journal:  Neuromolecular Med       Date:  2012-06-17       Impact factor: 3.843

5.  Endoplasmic reticulum stress induces a caspase-dependent N-terminal cleavage of RBX1 protein in B cells.

Authors:  Shimon Shteingart; Rivka Hadar; Itamar Cohen; Tommer Ravid; Boaz Tirosh
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

Review 6.  Cell biology. Metabolic control of cell death.

Authors:  Douglas R Green; Lorenzo Galluzzi; Guido Kroemer
Journal:  Science       Date:  2014-09-19       Impact factor: 47.728

7.  Identification of factors that function in Drosophila salivary gland cell death during development using proteomics.

Authors:  C K McPhee; B M Balgley; C Nelson; J H Hill; Y Batlevi; X Fang; C S Lee; E H Baehrecke
Journal:  Cell Death Differ       Date:  2012-08-31       Impact factor: 15.828

Review 8.  The role of X-box binding protein-1 in tumorigenicity.

Authors:  Ayesha N Shajahan; Rebecca B Riggins; Robert Clarke
Journal:  Drug News Perspect       Date:  2009-06

9.  Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma.

Authors:  Alex Vasuthasawat; Esther M Yoo; Kham R Trinh; Alan Lichtenstein; John M Timmerman; Sherie L Morrison
Journal:  MAbs       Date:  2016-06-30       Impact factor: 5.857

Review 10.  Targeting the ubiquitin system in cancer therapy.

Authors:  Daniela Hoeller; Ivan Dikic
Journal:  Nature       Date:  2009-03-26       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.